Aug. 28, 2025—Tempus AI is acquiring Paige for $81.25 million. Tempus says the acquisition allows the company to grow its data set, expand its technical team, and establish a footprint in digital pathology with an industry-leading technology portfolio. The acquisition is being paid primarily in Tempus common stock.
“As we embark upon building the largest foundation model that’s ever been built in oncology, the acquisition of Paige substantially accelerates our efforts,” Eric Lefkofsky, founder and CEO of Tempus, said in a press statement. “Paige is a leader in digital pathology and has amassed one of the most comprehensive digital pathology data sets in the world through its relationship with Memorial Sloan Kettering Cancer Center. We believe both the Paige team, with their deep generative AI experience, and the data set they have built will be catalytic across all of our AI efforts.”
Paige’s dataset includes almost 7 million digitized pathology slide images and associated clinical and molecular data. Tempus will also assume Paige’s remaining Microsoft Azure cloud services agreement.